Rhinomed Limited

Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise dedicated to the research, development, and market introduction of consumer and medical devices. Since its incorporation in 2004, the company has focused on creating wearable nasal technologies designed to optimize breathing, improve sleep quality, support general health, and assist in disease diagnosis. Its product offerings include the Turbine, which enhances athletic breathing; Mute, aimed at reducing snoring and promoting clearer airflow; Pronto, a vapor inhaler developed to aid airflow and sleep; and Rhinoswab, utilized for efficient nasal sample collection. Beyond these products, Rhinomed is actively engaged in developing programs across diverse fields such as sleep architecture, the cognitive impact of sleep and respiratory function, obstructive sleep apnea, pain and nausea relief, respiratory diseases, and advanced diagnostics and sensors. The company also provides a distinct drug delivery platform specifically for cannabinoid formulations. Formerly known as Consegna Group Limited, the company adopted the name Rhinomed Limited in November 2013.